Brian D. Richards, Psy.D., completed a Masters degree in Existential-Phenomenological Psychology at Duquesne University, a Psy.D. at the University of Denver School for Professional Psychology, and a Postdoctoral Fellowship at the Johns Hopkins Behavioral Pharmacology Research Unit, where he contributed to some of the original research administering psilocybin with cancer patients and healthy normal adults. Dr. Richards was formerly a Clinical Director with MedOptions, the largest behavioral health provider in the United States. He also provides Advanced Screenings at Oasis, an acute outpatient center in Maryland, and cares for patients with a cancer diagnosis at Maryland Oncology Hematology, The Aquilino Cancer Center. Dr. Richards was a Lead Trainer and Mentor for Compass Pathways (a UK-based Life Sciences Company), and he also mentors students at the California Institute for Integral Studies, the leading Psychedelic Medicine Certificate Program worldwide.
Dr. Richards was a Lead Psychologist on an innovative, simultaneous group administration high-dose psilocybin trial with Cancer patients at the Aquilino Cancer Center in Rockville, Maryland. This cutting-edge, purpose-built psychedelic medicine clinic—located in a busy outpatient oncology center, is the first of its kind in the world, and may serve as a prototype for future clinics nationwide.
Dr. Richards’ clinical and research interests include meaning-centered psychotherapy, mystical experience, brain science-based approaches to vibrant health and wellness, and working with treatment refractory patients. He finds joy and meaning practicing yoga, gourmet cooking, working in nature, growing medicinal mushrooms, and caring for wildlife and plants.
Selected Publications & Presentations:
Press Release on Our First Clinical Trial:
Clinical Perspectives in Managing High Dose Psilocybin Sessions – Brian Richards & Mary Cosimano:
1. Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research
Sara J. Tai, Elizabeth M. Nielson, Molly Lennard-Jones,
Riikka-Liisa Johanna Ajantaival, Rachel Winzer, William A. Richards,
Frederick Reinholdt, Brian D. Richards, Peter Gasser and Ekaterina Malievskaia
Frontiers in Psychiatry (2021)
2. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors
Griffiths, R.R., Johnson, M.W., Richards, W.A., Richards, B.D., Jesse, R., MacLean, K.A., Barrett, F.S., Cosimano, M.P., and Klinedinst, M.A.
Journal of Psychopharmacology (2017)
3. Psilocybin produces substantial and sustained decreases in depression and anxiety
in patients with life-threatening cancer: A randomized double-blind trial
Griffiths, R.R., Johnson, M.W., Carducci, M.A., Umbricht, A., Richards, W.A., Richards, B.D., Cosimano M.R and Klinedinst, M.A.
Journal of Psychopharmacology (2016)
Awarded 2020 Journal of Psychopharmacology Prize for having the highest number of citations of all original research articles published in Journal of Psychopharmacology in 2016.
4. Characterization of Individuals Seeking Treatment for Caffeine Dependence
Juliano, L. M., Evatt, D. P., Richards, B. D., & Griffiths, R. R.
Psychology of Addictive Behaviors (2012)
5. Psilocybin Occasioned Mystical-Type Experiences: Immediate and Persisting Dose-Related Effects
Roland R, Griffiths, Matthew W. Johnson, William A. Richards, Brian D. Richards, Una McCann, Robert Jesse
6. Relative Abuse Liability of GHB in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects of Supratherapeutic Doses of Triazolam, Pentobarbital, and GHB
Lawrence P. Carter, Brian D. Richards, Miriam Z Mintzer and Roland R Griffiths
Neuropsychopharmacology (2006), 1-15
My Telehealth link: